The DOAC rivaroxaban is a direct factor Xa inhibitor and was shown to be non-inferior to warfarin in the prevention of stroke/SE in patients with NVAF and to be associated with a similar risk of major bleeding and a lower risk of intracranial and fatal bleeding, in a global phase 3 clinical trial [7]. The gene discussed is F10; the disease is stroke disorder.